Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder CancerVisa övriga samt affilieringar
2022 (Engelska)Ingår i: Life, ISSN 2075-1729, Vol. 12, nr 8, artikel-id 1198Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Thromboembolic events (TEE) are high-risk complications in patients undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for urothelial muscle-invasive bladder cancer (MIBC). The purpose of the study was to investigate any differences in TEE-incidence, comparing peripherally inserted central catheter (PICC) versus a totally implanted port (PORT) as CVA (central venous access) during NAC. We identified 947 cystectomized MIBC-patients from four Swedish medical centers in 2009-2021. Inclusion criteria were cT2-T4aN0M0 and 375 patients were finally eligible and evaluated, divided into: NAC-administered (n = 283) resp. NAC-naïve-NAC-eligible (n = 92), the latter as tentative control group. Data on TEEs and types of CVA were retrospectively collected and individually validated, from final transurethral resection of the bladder tumor (TUR-B) to 30 days post-RC. Adjusted logistic regression and log rank test were used for statistical analyses. Amongst NAC-administered, 83% (n = 235) received PICCs and 15% (n = 42) PORTs. Preoperative TEEs occurred in 38 PICC-patients (16.2%) and in one PORT-patient (2.4%), with 47 individual events registered. We found a significantly increased odds ratio of TEE in NAC-administered PICC-patients compared to in PORT-patients (OR: 8.140, p-value: 0.042, 95% CI 1.078-61.455). Our findings indicate a greater risk for pre-RC TEEs with PICCs than with PORTs, suggesting favoring the usage of PORTs for MIBC-NAC-patients.
Ort, förlag, år, upplaga, sidor
MDPI, 2022. Vol. 12, nr 8, artikel-id 1198
Nyckelord [en]
central venous catheters, complications, cystectomy, neoadjuvant therapy, thromboembolism, urinary bladder neoplasms
Nationell ämneskategori
Klinisk medicin
Identifikatorer
URN: urn:nbn:se:umu:diva-198946DOI: 10.3390/life12081198ISI: 000845456700001PubMedID: 36013377Scopus ID: 2-s2.0-85138024911OAI: oai:DiVA.org:umu-198946DiVA, id: diva2:1690993
Forskningsfinansiär
VetenskapsrådetVästerbottens läns landsting, VLL RV-848051Cancerforskningsfonden i Norrland, CFF LP 13-20002022-08-292022-08-292025-02-18Bibliografiskt granskad